{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:38:32Z","timestamp":1793461112291,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["20192151"],"award-info":[{"award-number":["20192151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["20192151"],"award-info":[{"award-number":["20192151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Injection drug use is the primary mode of transmission of hepatitis C virus (HCV) infection in the developed world and guidelines recommend screening individuals with current or history of injection drug use for HCV; however, the majority of those living with HCV in Canada are not aware of their positive status. This low level of HCV status awareness suggests that screening is not effective with current testing strategies. The aim of this review is to determine what barriers and enablers people who inject drugs (PWID) experience surrounding testing for HCV to help inform the development of an engaging testing strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Comprehensive literature searches were conducted using Medline, Embase and CINAHL in February 2021. Included studies investigated the barriers and enablers to testing for HCV in PWID and the experiences of PWID in testing for HCV. Studies were included if they were qualitative or mixed-methods design, involved people with current injection drug use or those with a history of injecting drugs, and were written in the English language. Studies were compared and common themes were coded and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The literature search resulted in 1554 citations and ultimately nine studies were included. Common barriers included self-perception of low risk for HCV, fear of diagnosis, stigma associated with IV drug use and HCV, antipathy in relation to mainstream health care services, limited knowledge about HCV, lack of rapport with provider, lack of motivation or competing priority of drug use, and limited awareness of new treatment options. Common enablers to testing included increasing awareness of HCV testing and treatment and providing positive narratives around HCV care, positive rapport with provider, accessible testing options and individualized care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While there has been some qualitative research on barriers and enablers to testing for HCV in PWID more research is needed to focus on this research question as a primary objective in order to provide more understanding from the participant\u2019s perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-023-16017-8","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:01:52Z","timestamp":1685570512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs \u2013 a scoping review of the qualitative evidence"],"prefix":"10.1186","volume":"23","author":[{"given":"Cathy R.","family":"Balsom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah V.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"key":"16017_CR1","unstructured":"World Health Organization. Hepatitis C. World Health Organization. 2022. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Cited 2022 Dec 22."},{"key":"16017_CR2","unstructured":"World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. 2021. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240027077. Cited 2022 Dec 22"},{"issue":"9","key":"16017_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","volume":"17","author":"AL Cox","year":"2020","unstructured":"Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17(9):533\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"16","key":"16017_CR4","doi-asserted-by":"publisher","first-page":"E594","DOI":"10.1503\/cmaj.161521","volume":"189","author":"Canadian Task Force on Preventive Health Care","year":"2017","unstructured":"Canadian Task Force on Preventive Health Care. Recommendations on hepatitis C screening for adults. CMAJ. 2017;189(16):E594-604.","journal-title":"CMAJ"},{"issue":"82","key":"16017_CR5","first-page":"3","volume":"24","author":"M Rotermann","year":"2013","unstructured":"Rotermann M, Langlois K, Andonov A, Trubnikov M. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian health measures survey. Health Reports. 2013;24(82):3.","journal-title":"Health Reports"},{"key":"16017_CR6","first-page":"100215","volume":"9","author":"S Kherghehpoush","year":"2023","unstructured":"Kherghehpoush S, McKeirnan KC. The role of community pharmacies in the HIV and HCV care continuum. Explor Res Clin Soc Pharm. 2023;9:100215.","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"7","key":"16017_CR7","first-page":"432","volume":"11","author":"GR Lichtenstein","year":"2015","unstructured":"Lichtenstein GR. Advances in hepatitis C virus treatment. Gastroenterol Hepatol (N Y). 2015;11(7):432.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"16017_CR8","doi-asserted-by":"crossref","unstructured":"Thompson WW. Vital Signs: Hepatitis C Treatment Among Insured Adults \u2014 United States, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2022;71. Available from: https:\/\/www.cdc.gov\/mmwr\/volumes\/71\/wr\/mm7132e1.htm. Cited 2023 May 24","DOI":"10.15585\/mmwr.mm7132e1"},{"issue":"9","key":"16017_CR9","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jclinepi.2008.10.012","volume":"62","author":"M Sampson","year":"2019","unstructured":"Sampson M, McGowan J, Cogo E, Grimshaw J, Moher D, Lefebvre C. An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol. 2019;62(9):944\u201352.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"16017_CR10","first-page":"333","volume":"21","author":"M Harris","year":"2014","unstructured":"Harris M, McDonald B, Rhodes T. Hepatitis C testing for people who inject drugs in the United Kingdom: why is uptake so low? Drugs: education. Prevention and Policy. 2014;21(4):333\u201342.","journal-title":"Prevention and Policy"},{"issue":"7","key":"16017_CR11","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12869","volume":"25","author":"M Harris","year":"2018","unstructured":"Harris M, Bonnington O, Harrison G, Hickman M, Irving W, the HepCATT team. Understanding hepatitis C intervention success\u2014Qualitative findings from the HepCATT study. J Viral Hepatitis. 2018;25(7):762\u201370.","journal-title":"J Viral Hepatitis"},{"issue":"2","key":"16017_CR12","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/dar.12895","volume":"38","author":"H Coupland","year":"2019","unstructured":"Coupland H, White B, Bates A, Park JN, Iversen J, Maher L. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney Australia. Drug Alcohol Rev. 2019;38(2):177\u201384.","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"16017_CR13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jvh.13214","volume":"27","author":"C Phillips","year":"2020","unstructured":"Phillips C, Schulkind J, O\u2019Sullivan M, Edelman N, Smith HE, Verma S, et al. Improving access to care for people who inject drugs: Qualitative evaluation of project ITTREAT-An integrated community hepatitis C service. J Viral Hepat. 2020;27(2):176\u201387.","journal-title":"J Viral Hepat"},{"key":"16017_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.103019","volume":"88","author":"KM Ward","year":"2021","unstructured":"Ward KM, McCormick SD, Sulkowski M, Latkin C, Chander G, Falade-Nwulia O. Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration. Int J Drug Policy. 2021;88: 103019.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"16017_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/14659891.2019.1704076","volume":"25","author":"B Tofighi","year":"2020","unstructured":"Tofighi B, Lee JD, Sindhu SS, Chemi C, Leonard NR. Engagement in the hepatitis C care continuum among people who use drugs. J Subst Use. 2020;25(4):343\u20139.","journal-title":"J Subst Use"},{"issue":"1","key":"16017_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-11-1","volume":"11","author":"JA Barocas","year":"2014","unstructured":"Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014;11(1):1.","journal-title":"Harm Reduct J"},{"issue":"190","key":"16017_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"1","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u2018Hep C\u2019s like the common cold\u2019: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;1(190):246\u201354.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"16017_CR18","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/jvh.13087","volume":"26","author":"NH Latham","year":"2019","unstructured":"Latham NH, Pedrana A, Doyle JS, Howell J, Williams B, Higgs P, et al. Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs. J Viral Hepat. 2019;26(7):919\u201322.","journal-title":"J Viral Hepat"},{"issue":"1","key":"16017_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/109019819201900101","volume":"19","author":"A Stecker","year":"1992","unstructured":"Stecker A, McLeroy K, Goodman R, Bird S, McCormick L. Towards integrating qualitative and quantitative methods: an introduction. Health Edu Q. 1992;19(1):1\u20138 (Spring).","journal-title":"Health Edu Q"},{"issue":"1","key":"16017_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10597-005-2597-1","volume":"41","author":"TD Warner","year":"2005","unstructured":"Warner TD, Monaghan-Geernaert P, Battaglia J, Brems C, Johnson ME, Roberts LW. Ethical considerations in rural health care: a pilot study of clinicians in Alaska and New Mexico. Community Ment Health J. 2005;41(1):21\u201333.","journal-title":"Community Ment Health J"},{"issue":"6","key":"16017_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/infdis\/jiac049","volume":"226","author":"B Catlett","year":"2022","unstructured":"Catlett B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, Wheeler A, Khandaker-Hussain B, et al. Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of hepatitis C virus RNA: a systematic review. J Infect Dis. 2022;226(6):1005\u201321.","journal-title":"J Infect Dis"},{"key":"16017_CR22","unstructured":"Hepatitis C point-of-care testing: What is its impact on testing and linkage to care?. CATIE - Canada\u2019s source for HIV and hepatitis C information. 2023. Available from: https:\/\/www.catie.ca\/prevention-in-focus\/hepatitis-c-point-of-care-testing-what-is-its-impact-on-testing-and-linkage-0. Cited 2023 May 24"},{"key":"16017_CR23","unstructured":"Canadian Network on Hepatitis C Blue print Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination in Canada. 2019. Available from: https:\/\/www.canhepc.ca\/sites\/default\/files\/media\/documents\/blueprint_hcv_2019_05.pdf. Cited 2023 May 24"},{"key":"16017_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: a knowledge synthesis. Int J Drug Policy. 2021;96: 103247.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"16017_CR25","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12889-020-08719-0","volume":"20","author":"DV Kelly","year":"2020","unstructured":"Kelly DV, Kielly J, Hughes C, Gahagan J, Asghari S, Hancock S, et al. Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study. BMC Public Health. 2020;20(1):639.","journal-title":"BMC Public Health"},{"key":"16017_CR26","unstructured":"The APPROACH 2.0 Study. APPROACH. Available from: https:\/\/www.approachstudy.ca\/about-us. Cited 2023 May 24"},{"issue":"19","key":"16017_CR27","first-page":"E83","volume":"8","author":"DG Klepser","year":"2022","unstructured":"Klepser DG, Klepser ME, Peters PJ, Hoover KW, Weidle PJ. Implementation and evaluation of a collaborative, pharmacy-based hepatitis C and HIV screening program. Prev Chronic Dis. 2022;8(19):E83.","journal-title":"Prev Chronic Dis"},{"issue":"9","key":"16017_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S2468-1253(20)30120-5","volume":"5","author":"A Radley","year":"2020","unstructured":"Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020;5(9):809\u201318.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-16017-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16017-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T22:02:33Z","timestamp":1685570553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-16017-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["16017"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-16017-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2492176\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1038"}}